Adverse events, serious adverse events, assessments of clinical laboratory values, and vital sign measurements 12 months [clinicaltrials_resource:9649f9cb90cad62ccbcbb596a8f90678]
MLN4924 intravenous (IV) on a 21-day cycle on one of the following schedules:
Days 1, 3, and 5, followed by a rest period of 16 days (Schedule A)
Days 1, 4, 8, and 11, followed by a rest period of 10 days (Schedule B)
Continuous weekly dosing on Days 1, 8, and 15 (Schedule C)
Days 1, 4, 11, 15 for Cycle 1 only; Days 1, 4, 8, 11 for all subsequent cycles (Schedule D)
Dosing on Days 1, 3, and 5 in patients with high-grade MDS or AML (Schedule E)
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Adverse events, serious adverse events, assessments of clinical laboratory values, and vital sign measurements 12 months [clinicaltrials_resource:9649f9cb90cad62ccbcbb596a8f90678]
MLN4924 intravenous (IV) on a 21-day cycle on one of the following schedules:
Days 1, 3, and 5, followed by a rest period of 16 days (Schedule A)
Days 1, 4, 8, and 11, followed by a rest period of 10 days (Schedule B)
Continuous weekly dosing on Days 1, 8, and 15 (Schedule C)
Days 1, 4, 11, 15 for Cycle 1 only; Days 1, 4, 8, 11 for all subsequent cycles (Schedule D)
Dosing on Days 1, 3, and 5 in patients with high-grade MDS or AML (Schedule E)
Bio2RDF identifier
9649f9cb90cad62ccbcbb596a8f90678
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:9649f9cb90cad62ccbcbb596a8f90678
measure [clinicaltrials_vocabulary:measure]
Adverse events, serious advers ...... s, and vital sign measurements
time frame [clinicaltrials_vocabulary:time-frame]
description
MLN4924 intravenous (IV) on a ...... or AML (Schedule E)
identifier
clinicaltrials_resource:9649f9cb90cad62ccbcbb596a8f90678
title
Adverse events, serious advers ...... al sign measurements 12 months
@en
type
label
Adverse events, serious advers ...... 9f9cb90cad62ccbcbb596a8f90678]
@en